iRadimed Corporation (NASDAQ:IRMD) Given Average Recommendation of “Buy” by Brokerages

Shares of iRadimed Corporation (NASDAQ:IRMD) have been assigned an average rating of “Buy” from the five research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $120.00.

Several equities analysts have commented on the company. Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $100.38, for a total value of $501,900.00. Following the transaction, the chief executive officer owned 2,235,000 shares of the company’s stock, valued at $224,349,300. This represents a 0.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 55,000 shares of company stock valued at $5,031,903. Corporate insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Hedge funds have recently bought and sold shares of the business. Tudor Investment Corp ET AL bought a new position in shares of iRadimed during the 3rd quarter worth $666,000. SG Americas Securities LLC grew its position in shares of iRadimed by 88.6% during the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after buying an additional 33,072 shares in the last quarter. RFG Advisory LLC bought a new position in shares of iRadimed during the 4th quarter worth $1,594,000. Baader Bank Aktiengesellschaft bought a new position in shares of iRadimed during the 4th quarter worth $595,000. Finally, Bridge City Capital LLC grew its position in shares of iRadimed by 19.4% during the 4th quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after buying an additional 11,509 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Performance

NASDAQ:IRMD opened at $92.20 on Friday. The stock’s fifty day moving average is $90.47 and its 200 day moving average is $95.85. iRadimed has a fifty-two week low of $55.11 and a fifty-two week high of $107.90. The firm has a market capitalization of $1.18 billion, a PE ratio of 50.38 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.03. The company had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts forecast that iRadimed will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. iRadimed’s dividend payout ratio is 43.72%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.